A PYMNTS Company

Pennsylvania AG Secures Millions in Drug Price-Fixing Case Against Generic Manufacturers

By  |  February 3, 2026
price-fixing

Pennsylvania has joined a broad coalition of states in reaching $17.85 million in settlements with generic drug manufacturers Lannett Company, Inc. and Bausch Health, according to a statement from the office of Dave Sunday. The agreements address allegations that the two companies coordinated to raise prices and suppress competition for widely used generic medicines.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Per a statement released by the Attorney General’s Office, the settlements resolve claims that the companies took part in a long-running effort to manipulate prices of certain prescription drugs sold across the country, including in Pennsylvania, between May 2009 and December 2019. The state said the conduct affected consumers who depend on lower-cost generics to manage everyday health needs.

    As part of the deals, Lannett and Bausch have agreed to assist with ongoing litigation targeting other drugmakers and executives who are alleged to have been involved in similar conduct, according to a statement. The companies will also implement internal compliance measures designed to strengthen adherence to antitrust laws.

    “Pennsylvania consumers rely on generic medications to keep health care affordable,” Attorney General Sunday said. “When companies illegally raise prices and eliminate competition, families, seniors, and patients on fixed incomes pay the price. This settlement helps return money to Pennsylvanians who were overcharged and sends a clear message that drug companies will be held accountable for putting profits over people.”

    Related: Utah Reaches Antitrust Settlement With Sandoz Over Generic Drug Pricing

    The latest agreements follow earlier multistate settlements that together reached $49.1 million, per a statement from the coalition. Pennsylvania remains involved in continuing antitrust cases against numerous pharmaceutical manufacturers, and state officials say the first of those trials is expected in late 2026.

    The multistate group is also expanding its legal actions. A coalition of 42 states and territories, including Pennsylvania, plans to file a new lawsuit against Novartis and its generic-drug subsidiary Sandoz, according to a statement. The forthcoming complaint alleges the companies coordinated to fix prices, divide markets, and rig bids for dozens of generic medications sold nationwide.

    State officials say Pennsylvanians who bought generic prescription drugs produced by Lannett or Bausch during the May 1, 2009, to December 31, 2019, period may qualify for compensation. Additional details on eligibility and the claims process are expected to be released as the settlement administration moves forward, per a statement from the Attorney General’s Office.

    Source: Attorney General